URINARY INCONTINENCE TREATMENT DRUGS MARKET ANALYSIS

Urinary Incontinence Treatment Drugs Market, By Incontinence Type (Urge Incontinence, Stress Incontinence, Over-flow Incontinence, Mixed Incontinence, Other Incontinence Type), By Drug Class (Anticholinergic/Antispasmodic Agents, Skeletal Muscle Relaxants, Antidepressants, Alpha Blockers, Topical Estrogens, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Global Urinary Incontinence Treatment Drugs Market: Key Developments

In April 2022, Axonics, Inc., a medical technology company that develops and markets novel products to treat bladder and bowel dysfunction, announced the launch of its direct-to-consumer television advertising campaign.
In February 2022, Kimberly-Clark Corporation, the pioneer of menstrual hygiene products, announced that it had completed the acquisition of a majority stake in Thinx, Inc., an industry disruptor and leader in the reusable period and incontinence underwear category. The company made its first minority investment in Thinx in 2019.
In January 2022, according to the data published by the International Trade Administration, Chile healthcare expenses was US$ 13.50 billion in 2021, indicating increaseof 8.9% from expenses in 2020, which was US$ 12.29 billion.
In March 2021, according to the data published by the National Center for Biotechnology Information, urinary tract infection accounts for 1 Mn emergency department visits, and over 100,000 hospitalizations annually in the U.S.

Urinary Incontinence Treatment Drugs Market Report Snapshots